http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics
-
Senti Biosciences Announces New Employment Inducement Grants
-
Senti Biosciences (SNTI) Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202
-
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hem
-
Senti Biosciences (SNTI) Appoints Fran Schulz to its Board
-
Senti Bio Appoints Fran Schulz to Board of Directors
-
Senti Bio to Participate in Upcoming Investor Conferences
-
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
-
Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202
-
Senti Biosciences (SNTI) Announces 1-for-10 Reverse Stock Split
-
Senti Bio Announces Reverse Stock Split
-
Senti Biosciences (SNTI) Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
-
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
-
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
-
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
-
Senesco Technologies (SNTI) Announces Publication of SENTI-202 Preclinical Data
-
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
-
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
-
Senesco Technologies (SNTI) Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
-
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
-
Senesco Technologies (SNTI) Announces FDA Clearance of IND Application for SENTI-202
-
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
-
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
-
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
-
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
-
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting
-
Senti Bio to Participate in Upcoming Conferences
-
Senti Bio to Participate in Upcoming Investor Conferences
-
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
-
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners
-
Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
-
Senti Bio Announces First Quarter 2023 Results and Pipeline Updates
-
Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting
-
Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting
-
Senesco Technologies, Inc. (SNTI) Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting
-
Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting
-
Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting
-
Senti Bio to Participate in Upcoming Investor Conferences
-
Senti Bio to Participate in Upcoming Investor Conferences
-
Senti Bio to Present at the SVB Securities Global Biopharma Conference
-
Senti Bio to Present at the SVB Securities Global Biopharma Conference
-
Senesco Technologies, Inc. (SNTI) Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
-
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
-
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
-
Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
-
Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference
-
Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event
-
Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event
-
Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting
-
Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting
